146 related articles for article (PubMed ID: 37544813)
1. Corrigendum to "Biomimetic amphiphilic FAAP NPs nanoparticles: Synthesis, characterization and antivirus activity" [Int. Immunopharmacol. 101(Part A) (2021) 108047].
Li X; Zhang Z; Ma X; Guo Z; Ban X; Tian Z; Zhao L; Liu Q; He Q
Int Immunopharmacol; 2023 Sep; 122():110735. PubMed ID: 37544813
[No Abstract] [Full Text] [Related]
2. Biomimetic amphiphilic FAAP NPs nanoparticles: Synthesis, characterization and antivirus activity.
Li XH; Zhang Z; Ma X; Guo ZH; Ban X; Tian Z; Zhao L; Liu Q; He Q
Int Immunopharmacol; 2021 Dec; 101(Pt A):108047. PubMed ID: 34619499
[TBL] [Abstract][Full Text] [Related]
3. Retraction notice to "Corrigendum to "MLL1 promotes migration and invasion of fibroblast-like synoviocytes in rheumatoid arthritis by activating the TRIF/NF-κB signaling pathway via H3K4me3 enrichment in the TLR4 promoter region"" [Int. Immunopharmacol. 82 (2020) 106220] [Int. Immunopharmacol. 92 (2021) 107321].
Zhang Y; Ji T; Ma S; Wu W
Int Immunopharmacol; 2023 Apr; 117():109865. PubMed ID: 36822094
[No Abstract] [Full Text] [Related]
4. Corrigendum to "In vivo anti-apoptosis activity of novel berberine-loaded chitosan nanoparticles effectively ameliorates osteoarthritis" [Int. Immunopharmacol. 28(1) (2015) 34-43].
Zhou Y; Liu SQ; Peng H; Yu L; He B; Zhao Q
Int Immunopharmacol; 2022 Jul; 108():108844. PubMed ID: 35562271
[No Abstract] [Full Text] [Related]
5. Corrigendum to "In vivo anti-apoptosis activity of novel berberine-loaded chitosan nanoparticles effectively ameliorates osteoarthritis" [Int. Immunopharmacol. 28(1) (2015) 34-43].
Zhou Y; Liu SQ; Peng H; Yu L; He B; Zhao Q
Int Immunopharmacol; 2020 Sep; 86():106796. PubMed ID: 32674050
[No Abstract] [Full Text] [Related]
6. Corrigendum to "Cynapanoside A exerts protective effects against obesity-induced diabetic nephropathy through ameliorating TRIM31-mediated inflammation, lipid synthesis and fibrosis" [Int. Immunopharmacol. 113 (Part B) (2022) 109395].
Luo J; Tan J; Zhao J; Wang L; Liu J; Dai X; Sun Y; Kuang Q; Hui J; Chen J; Kuang G; Chen S; Wang Y; Ge C; Xu M
Int Immunopharmacol; 2023 Dec; 125(Pt A):111119. PubMed ID: 37907388
[No Abstract] [Full Text] [Related]
7. Corrigendum to "Electrochemical nanobiosensor based on reduced graphene oxide and gold nanoparticles for ultrasensitive detection of microRNA-128" [Int. J. Immunopharmacol. 117 (2023) 109960].
Mohammadnejad J; Basirhaghighi N; Yazdian F; Pourmadadi M; Shayeh JS; Omidi M; Mirshafiei M; Rahdar A; Díez-Pascual AM
Int Immunopharmacol; 2024 Jun; 134():112213. PubMed ID: 38719728
[No Abstract] [Full Text] [Related]
8. Corrigendum to "Photothermic therapy with cuttlefish ink-based nanoparticles in combination with anti-OX40 mAb achieve remission of triple-negative breast cancer" [Int. Immunopharmacol. 115 (2023) 109622].
Momenzadeh N; Hajian S; Shabankare A; Ghavimi R; Kabiri-Samani S; Kabiri H; Hesami-Zadeh K; Shabankareh ANT; Nazaraghay R; Nabipour I; Mohammadi M
Int Immunopharmacol; 2023 Nov; 124(Pt B):111035. PubMed ID: 37858486
[No Abstract] [Full Text] [Related]
9. Corrigendum to "Rapamycin regulates osteogenic differentiation through Parkin-mediated mitophagy in rheumatoid arthritis" [Int. Immunopharmacol. 113(Part B) (2022) 109407].
Chen Q; Fan K; Song G; Wang X; Zhang J; Chen H; Qin X; Lu Y; Qi W
Int Immunopharmacol; 2023 Nov; 124(Pt A):110941. PubMed ID: 37718175
[No Abstract] [Full Text] [Related]
10. Corrigendum to "Exosomal circRNA-001264 promotes AML immunosuppression through induction of M2-like macrophages and PD-L1 overexpression" [Int. Immunopharmacol. 124(Part A) (2023) 110868].
Du A; Yang Q; Sun X; Zhao Q
Int Immunopharmacol; 2024 Feb; 128():111442. PubMed ID: 38185544
[No Abstract] [Full Text] [Related]
11. Corrigendum to "Berberine derivative DCZ0358 induced oxidative damage by ROS-mediated JNK signaling in DLBCL cells" [Int. Immunopharmacol. 125(Part A) (2023) 111139].
Feng Q; Hu K; Hu H; Lu Y; Zhang H; Wang G; Zhang Q; Xu Z; Gao X; Jia X; Zhu H; Song D; Yi H; Peng Y; Wu X; Li B; Zhu W; Shi J
Int Immunopharmacol; 2024 Jun; ():112499. PubMed ID: 38909009
[No Abstract] [Full Text] [Related]
12. Corrigendum to "Oridonin regulates the polarized state of Kupffer cells to alleviate nonalcoholic fatty liver disease through ROS-NF-κB" [Int. Immunopharmacol. 101(Part B) (2021) 108290].
Zhu Y; Ruan S; Shen H; Guan Q; Zhai L; Yang Y
Int Immunopharmacol; 2023 Jun; 119():110302. PubMed ID: 37193623
[No Abstract] [Full Text] [Related]
13. Corrigendum to "Integrated population pharmacokinetics of immunoglobulin G following intravenous or subcutaneous administration of various immunoglobulin products in patients with primary immunodeficiencies" [Int. Immunopharmacol. 113(Part A) (2022) 109331].
Li Z; Follman K; Freshwater E; Engler F; Yel L
Int Immunopharmacol; 2023 Jan; 114():109555. PubMed ID: 36527876
[No Abstract] [Full Text] [Related]
14. Corrigendum to "Immune response of C57BL/6J mice to herpes zoster subunit vaccines formulated with nanoemulsion-based and liposome-based adjuvants" [Int. Immunopharmacol. 101(Part B) (2021) 108216].
He L; Sun B; Guo Y; Yan K; Liu D; Zang Y; Jiang C; Zhang Y; Kong W
Int Immunopharmacol; 2023 Jun; 119():110260. PubMed ID: 37150708
[No Abstract] [Full Text] [Related]
15. Corrigendum to "Tryptase inhibitor APC 366 prevents hepatic fibrosis by inhibiting collagen synthesis induced by tryptase/protease-activated receptor 2 interactions in hepatic stellate cells" [Int. Immunopharmacol. 20 (2014) 352-357].
Lu J; Chen B; Li S; Sun Q
Int Immunopharmacol; 2019 Apr; 69():408. PubMed ID: 30755386
[No Abstract] [Full Text] [Related]
16. Corrigendum to "Plasma levels of 12 different cytokines correlate to PD-1 inhibitor combined chemotherapy responses in advanced non-small-cell lung cancer patient" [Int. Immunopharmacol. 124(Part A) (2023) 110888].
Peng Y; Qi Q; Zhu M; Zhang Y; Bao Y; Liu Y
Int Immunopharmacol; 2023 Nov; 124(Pt A):110976. PubMed ID: 37778965
[No Abstract] [Full Text] [Related]
17. Corrigendum to "(E)-2-methoxy-4-(3-(4-methoxyphenyl)prop-1-en-1-yl)phenol alleviates inflammatory responses in LPS-induced mice liver sepsis through inhibition of STAT3 phosphorylation" [Int. Immunopharmacol. 125(Part B) (2023) 111124].
Kim B; Yu JE; Yeo IJ; Son DJ; Lee HP; Roh YS; Lim KH; Yun J; Park H; Han SB; Hong JT
Int Immunopharmacol; 2024 Jun; ():112543. PubMed ID: 38926074
[No Abstract] [Full Text] [Related]
18. Corrigendum to "Sinapic acid and 3,3'-diindolylmethane potentiate cyclophosphamide antitumor activity through induction of apoptosis and inhibition of metastasis" [Int. Immunopharmacol. 118 (2023) 110074].
Othman AM; Abdel-Rahman N; Denewer M; Eissa LA
Int Immunopharmacol; 2023 Jun; 119():110234. PubMed ID: 37121793
[No Abstract] [Full Text] [Related]
19. Corrigendum to "Evaluation of the immunomodulatory and anti-inflammatory activity of Bakuchiol using RAW 264.7 macrophage cell lines and in animal models stimulated by lipopolysaccharide (LPS)" [Int. Immunopharmacol. 91 (2021) 107264].
Kumar A; Sawhney G; Kumar Nagar R; Chauhan N; Gupta N; Kaul A; Ahmed Z; Sangwan PL; Satheesh Kumar P; Yadav G
Int Immunopharmacol; 2022 Oct; 111():109003. PubMed ID: 35778365
[No Abstract] [Full Text] [Related]
20. Corrigendum to 'In-vitro and in-vivo anti-breast cancer activity of synergistic effect of berberine and exercise through promoting the apoptosis and immunomodulatory effects' [Int. Immunopharmacol. 87 (2020) 106787].
Ma W; Zhang Y; Yu M; Wang B; Xu S; Zhang J; Li X; Ye X
Int Immunopharmacol; 2020 Nov; 88():106899. PubMed ID: 32827917
[No Abstract] [Full Text] [Related]
[Next] [New Search]
